Private Advisor Group LLC Increases Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Private Advisor Group LLC boosted its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 238.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,716 shares of the specialty pharmaceutical company’s stock after buying an additional 5,437 shares during the quarter. Private Advisor Group LLC’s holdings in Jazz Pharmaceuticals were worth $860,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of JAZZ. First Trust Direct Indexing L.P. boosted its position in shares of Jazz Pharmaceuticals by 54.1% during the first quarter. First Trust Direct Indexing L.P. now owns 2,740 shares of the specialty pharmaceutical company’s stock worth $330,000 after buying an additional 962 shares during the period. Commonwealth Equity Services LLC raised its stake in Jazz Pharmaceuticals by 21.4% during the 1st quarter. Commonwealth Equity Services LLC now owns 13,158 shares of the specialty pharmaceutical company’s stock valued at $1,585,000 after purchasing an additional 2,318 shares during the period. Janney Montgomery Scott LLC increased its stake in shares of Jazz Pharmaceuticals by 45.1% in the first quarter. Janney Montgomery Scott LLC now owns 15,888 shares of the specialty pharmaceutical company’s stock worth $1,913,000 after acquiring an additional 4,939 shares during the last quarter. Daiwa Securities Group Inc. increased its stake in shares of Jazz Pharmaceuticals by 18.7% in the first quarter. Daiwa Securities Group Inc. now owns 5,586 shares of the specialty pharmaceutical company’s stock worth $673,000 after acquiring an additional 879 shares during the last quarter. Finally, Wright Investors Service Inc. bought a new stake in Jazz Pharmaceuticals in the first quarter worth $442,000. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Trading Up 0.4 %

JAZZ opened at $110.45 on Friday. The firm’s fifty day simple moving average is $110.68 and its 200 day simple moving average is $109.56. The company has a current ratio of 2.37, a quick ratio of 2.02 and a debt-to-equity ratio of 1.36. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $134.48. The stock has a market capitalization of $6.82 billion, a P/E ratio of 18.98, a P/E/G ratio of 1.38 and a beta of 0.57.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 EPS for the quarter, beating analysts’ consensus estimates of $3.80 by $0.87. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1 billion. As a group, research analysts anticipate that Jazz Pharmaceuticals plc will post 16.02 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Robert W. Baird decreased their price target on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating for the company in a report on Thursday, August 1st. Morgan Stanley cut their target price on shares of Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating for the company in a research note on Friday, July 12th. JPMorgan Chase & Co. raised their price target on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a report on Monday, August 19th. Royal Bank of Canada lifted their target price on shares of Jazz Pharmaceuticals from $175.00 to $179.00 and gave the stock an “outperform” rating in a report on Wednesday, October 23rd. Finally, Wells Fargo & Company lowered their target price on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating for the company in a report on Thursday, August 1st. Three investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $173.43.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the transaction, the senior vice president now owns 14,531 shares in the company, valued at $1,573,707.30. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.20% of the stock is owned by company insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.